Alecensa 150 MG capsule UU 240S
Ended Awarded
- Contract number
- SPE2DB26FDD72
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,565
Award facts
- Contract value 100% obligated
- $25,564.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units) valued at $25,564.64. This firm fixed-price delivery order, awarded on October 20, 2025, with an ultimate completion date of November 10, 2025, was issued without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal pharmaceutical procurement. The order falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.999 billion ceiling and extends through December 31, 2036.
DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier within the Department of Defense's broader $30.3 billion PPV-G GEN V acquisition strategy, which authorizes the company to provide firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare facilities worldwide. The company's established track record supplying specialized pharmaceuticals—including oncology treatments, immunosuppressants, biologics, vaccines, and emergency medications—across numerous delivery orders demonstrates its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FDD72?
SPE2DB26FDD72 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 20, 2025.
How much is contract SPE2DB26FDD72 worth?
The government has obligated $25,565 on SPE2DB26FDD72.
Is contract SPE2DB26FDD72 an order under another contract?
Yes. SPE2DB26FDD72 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB26FDD72 competed?
The extent of competition for SPE2DB26FDD72 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award